

Development of Immunoferritin Cellem001 with Dual Immune Checkpoints Blockade and T/NK-tumor Cell Engager



ONCOLOGY	Preclinical
Product Type	Recombinant Protein
Indication	NSCLC, Melanoma
Target	PD-L1, TIGIT
MoA(Mechanism of Action)	1) Simultaneous inhibition of PD-L1 + TIGIT 2) T-, NK cell co-activation 3) Engager ability between cancer and immune cells
Competitiveness	1) Excellent MOA, differentiated from current clinical immunotherapeutics 2) Significantly reduced immune-related adverse-effects 3) Low treatment cost due to cost-effective manufacturing 4) High thermal and storage stability
Development Stage	Preclinical
Route of Administration	Intravenous injection